期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血小板P2Y_(12)受体拮抗剂的研究进展 被引量：5

Research progress of P2Y_(12) receptor antagonists
原文传递
导出
摘要 血小板聚集在血栓形成过程中发挥关键作用,抗血小板药物是预防和治疗动脉粥样硬化疾病患者发生严重心血管事件的重要基石。P2Y12受体拮抗剂是一类重要的抗血小板药物,近年来成为研究的热点并在临床上广泛应用。本文结合最新研究进展,对P2Y12受体拮抗剂作用机制、药理学特征、临床疗效及安全性进行综述,以期为临床合理用药提供参考。 Platelet aggregation plays a key role in the processes of platelet activation and thrombosis. Antiplatelet therapy is the main cornerstone for the treatment and prevention of major cardiovascular events for patients with atherosclerotic disease. P2Y12 receptor antagonists, as an important class of antiplatelet agents, has been a hot area of research in recent years, which has been widely used. This review focused on the mechanism of action, pharmacological properties, current clinical efficiency and safety.
作者 王思铭 张丽华 张海波
机构地区 阜外心血管病医院中国牛津国际医学研究中心
出处 《中华临床医师杂志（电子版）》 CAS 2014年第22期184-189,共6页 Chinese Journal of Clinicians(Electronic Edition)
关键词 血栓形成 动脉粥样硬化 抗血小板聚集抑制剂 P2Y12受体拮抗剂 Thrombosis Atherosclerosis Platelet aggregation inhibitors P2Y12 receptor antagonists
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献38

  • 1Tunstall-Pedoe H,Kuulasmaa K,Mhnen M,et al.Contribution of Trends in Survival and Coronar Y-Event Rates to Changes in Coronary Heart Disease Mortality:10-Year Results from 37 Who Monica Project Populations[J].Lancet,1999,353(9164):1547-1557.
  • 2Group WB.Toward a Healthy and Harmonious Life in China:Stemming the Rising Tide of Non-Communicable Diseases[N/OL].http://www.worldbank.org/en/news/feature/2011/07/26/towardhealth-harmonious-life-china-stemming-rising-tide-of-non-communi cable-diseases(accessed 27/03,2014)(Type of Medium),2011.
  • 3Tan GM,Lam YY,Yan BP.Novel Platelet ADP P2Y12 Inhibitors in the Treatment of Acute Coronary Syndrome[J].Cardiovasc Ther,2012,30(4):e167-173.
  • 4Balsano F,Rizzon P,Violi F,et al.Antiplatelet Treatment with Ticlopidine in Unstable Angina.A Controlled Multicenter Clinical Trial.The Studio Della Ticlopidina Nell'angina Instabile Group[J].Circulation,1990,82(1):17-26.
  • 5Cosmi B,Rubboli A,Castelvetri C,et al.Ticlopidine Versus Oral Anticoagulation for Coronary Stenting[J].Cochrane Database Syst Rev,2001(4):CD002133.
  • 6Leon MB,Baim DS,Popma JJ,et al.A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stentin[J].New Engl J Med,1998,339(23):1665-1671.
  • 7Gent M,Donald Easton J,Hachinski V,et al.The Canadian American Ticlopidine Study(Cats)in Thromboembolic Stroke[J].Lancet,1989,333(8649):1215-1220.
  • 8Sabatine MS,Cannon CP,Gibson CM,et al.Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with St-Segment Elevation[J].New Engl J Med,2005,352(12):1179-1189.
  • 9Chen ZM,Jiang LX,Chen YP,et al.Addition of Clopidogrel to Aspirin in 45,852 Patients with Acute Myocardial Infarction:Randomised Placebo-Controlled Trial[J].Lancet,2005,366(9497):1607-1621.
  • 10Antman EM,Hand M,Armstrong PW,et al.2007 Focused Update of the Acc/Aha 2004 Guidelines for the Management of Patients with St-Elevation Myocardial Infarction:A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines:Developed in Collaboration with the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians:2007 Writing Group to Review New Evidence and Update the Acc/Aha 2004 Guidelines for the Management of Patients with St-Elevation Myocardial Infarction,Writing on Behalf of the 2004 Writing Committee[J].Circulation,2008,117(2):296-329.

二级参考文献10

  • 1Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery ( EACTS ), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J,2010 , 31:2501-2555.
  • 2Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation, 2011, 124 :e574-651.
  • 3Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coil Cardiol, 2011,58 :e123-210.
  • 4Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation ( EuroSCORE ). Eur J Cardiothorac Surg, 1999,16:9-13.
  • 5Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009,360:961- 972.
  • 6Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coil Cardiol,2010,55:1923-1932.
  • 7Online STS fish calculator [ S/OL]. [ 2012-01-01 ]. http:// riskcalc, sts. org/STSWebRiskCalc273/de, aspx.
  • 8Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes ( CURRENT-OASIS 7 ): a randomised factorial trial. Lancet,2010,376 : 1233-1243.
  • 9Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Cell Cardiol,2007,50 : 1742-1751.
  • 10Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation, 2011,123:2736-2747.

共引文献425

同被引文献94

  • 1饶贤才,胡福泉.基因串联体的构建策略及其表达模式[J].医学研究生学报,2006,19(6):557-560. 被引量：8
  • 2乔德永,霍建丽,杨天雨,等.抗血栓生化药物的研究进展[J].药用生物技术,2009,16(5):477-480.
  • 3陈灏珠,林果为,王吉耀实用内科学[M].14版北京:人民卫生出版社:2013:9.
  • 4MICHOS ED,ARDEHALI R,BLUMENTHAL RS, et al. Aspirin and clopidogrel resistance [ C ~//Mayo Clinic Proceedings. Elsevier, 2006,81 (4) :518 -526.
  • 5ANGIOLILLO DJ, FERNANDEZ-ORTIZ A, BERNARDO E, et al. Variability in individual responsiveness to clopidogrel: clini- cal implications, management, and future perspectives[ J]. J Am College Cardiol, 2007,49 ( 14 ) : 1505 - 1516.
  • 6GEISLER T, GAWAZ M. Variable response to clopidogrel in pa- tients with coronary artery disease [ C ]//Seminars in thrombosis and hemostasis. 2007, 33 (2) : 196 - 202.
  • 7TAN GM, LAM YY, YAN BP. Novel platelet ADP P2Y12 in- hibitors in the treatment of acute coronary syndrome[ J]. Cardio- vasc Therap, 2012,30(4) : e167 -e173.
  • 8BRANDT JT, PAYNE CD, WIVIOTT SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite for- mation [ J~. Am Heart J, 2007,153 ( I ) :66. e9 - 66. el6.
  • 9SUGIDACHI A, OGAWA T, KURIHARA A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with simi- lar antiplatelet activity to that of clopidogrel's active metabolite [ J]. J Thrombos Haemostas, 2007,5(7) : 1545 -1551.
  • 10ROE MT, ARMSTRONG PW, FOX K AA, et al. Prasugrel ver- sus clopidogrel for acute coronary syndromes without revascular- ization[ J]. New Engl J Med, 2012, 367 (14) : 1297 - 1309.

引证文献5

二级引证文献43

中华临床医师杂志（电子版）
2014年 第22期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部